Payment overview · 2025
General Payments
$963.64
44 reported records · 10 companies
Healthcare provider profile · identity verified
Vipin Ohri, MD
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · WARSAW, NY · NPI 1770535064
Verified facts
What the public records show
CMS Open Payments records show Vipin Ohri, MD received $963.64 in general payments during 2025 across 44 reported records.
BIOTRONIK INC. accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $347.91 | 36.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.66 | 18.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.03 | 15.2% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.71 | 10.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.80 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.73 | 4.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.88 | 4.0% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$36.69 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.23 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $963.64 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $146.03 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.03 | 8 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $128.55 | 6 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $110.39 | 3 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $108.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.55 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.53 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.58 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.34 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.02 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $10.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 350 | 90 |
| Losartan Potassium | Losartan Potassium | 299 | 89 |
| Omeprazole | Omeprazole | 291 | 84 |
| Metformin Hcl | Metformin Hcl | 267 | 65 |
| Potassium Chloride | Potassium Chloride | 257 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 61 |
| Lisinopril | Lisinopril | 210 | 55 |
| Eliquis | Apixaban | 163 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 44 |
| Gabapentin | Gabapentin | 145 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 27 |
| Spironolactone | Spironolactone | 135 | 33 |
| Allopurinol | Allopurinol | 126 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 47 |
| Furosemide | Furosemide | 119 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 29 |
| Farxiga | Dapagliflozin Propanediol | 107 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 31 |
| Atenolol | Atenolol | 103 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 26 |
| Jardiance | Empagliflozin | 93 | 18 |
| Glimepiride | Glimepiride | 85 | 22 |
| Sertraline Hcl | Sertraline Hcl | 84 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 18 |
| Warfarin Sodium | Warfarin Sodium | 81 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 26 |
| Simvastatin | Simvastatin | 78 | 23 |
| Digoxin | Digoxin | 76 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 24 |
| Xarelto | Rivaroxaban | 76 | 14 |
| Alendronate Sodium | Alendronate Sodium | 75 | 12 |
| Tramadol Hcl | Tramadol Hcl | 72 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Ezetimibe | Ezetimibe | 68 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 14 |
| Ozempic | Semaglutide | 66 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 23 |
| Famotidine | Famotidine | 62 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Amoxicillin | Amoxicillin | 43 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 36 |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $963.64 · 44 records | BIOTRONIK INC. | AIRSUPRA, AMVIA EDGE, AREXVY, Acticor 7 VR-T DX, BIOMONITOR, BREZTRI, FARXIGA, JARDIANCE, LOKELMA, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error